期刊文献+

易瑞沙治疗晚期肺腺癌12例临床观察 被引量:1

下载PDF
导出
摘要 目的观察易瑞沙治疗晚期肺腺癌的临床效果和毒副作用。方法选取12例晚期肺腺癌患者,应用易瑞沙治疗1个月,观察其治疗效果和毒副作用。结果全组12例病例,1例CR,5例PR,3例SD,3例PD,疾病控制率(CR+PR+SD)为75%(9/12)。但2例脑转移的病例其脑转移结节未见明显的综小。肿瘤相关的症状缓解率为66.67%(8/12)。全组未见明显的毒副作用。结论易瑞沙治疗晚期肺腺癌的效果好,毒副作用轻,且大多能耐受。
出处 《右江民族医学院学报》 2008年第2期216-217,共2页 Journal of Youjiang Medical University for Nationalities
  • 相关文献

参考文献8

  • 1Barton J,Blackledge G,Wakeling A.Growth factors and their receptors:new targets for prostate cancer therapy[J].Urology,2001,58(2 suppl 1):114-122.
  • 2Ruffin CG,Harris KL.Gefitinib:the fist in a new class of agents for non-small cell lung cancer[J].Drug forecast,2003,28:462-465.
  • 3Baselga J.Targeting the epidermal growth factor recepter with tyrosine kinase inhibitor:small molecules,Big Hops[J].J Clin Oncol,2002,20:2217-2219.
  • 4Fukuoka M,Yano S,Giaccone G,et al.Multi-Institutional randomized phaseⅡ trial of Gefitinib for previously treated patients with advanced non-small-cell-lung cancer (The IDEAL I Trial)[corrected][J].J Clin Oncol,2003,21(12):2237-2246.
  • 5吴一龙,杨学宁,杨衿记,黄玉娟.中国的非小细胞肺癌Gefitinib分子靶向治疗[J].中国肺癌杂志,2004,7(4):318-320. 被引量:15
  • 6申东兰,郑海霞,陈晓秋,王芬.易瑞沙治疗晚期非小细胞肺癌的临床获益分析[J].肿瘤防治杂志,2005,12(20):1563-1566. 被引量:5
  • 7Chiu CH,Tsui CM,Chen YM,et al.Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response in related to skin toxicity[J].Lung Cancer,2005,47(1):129-138.
  • 8张品良,陈黎.易瑞沙治疗晚期非小细胞肺癌53例疗效观察[J].中华肿瘤防治杂志,2006,13(11):851-854. 被引量:8

二级参考文献18

  • 1王彬,张湘茹,储大同.易瑞沙在晚期非小细胞肺癌化疗失败后的作用[J].中华肿瘤杂志,2004,26(12):742-745. 被引量:53
  • 2Kholodenko B N,Demin O V,Moehren G,et al.Quantification of short term signaling by the epidermal growth factor receptor[J].J Biol Chem,1999,274(42):30169-30181.
  • 3陆瞬.非小细胞肺癌综合治疗新进展[A].张灿珍.中国临床肿瘤教育专辑[C].昆明:云南科技出版社,2004.51-53.
  • 4Lynch T J,Bell D w,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350(21):2129-2139.
  • 5Schiller J H.New directions for ZD1839 in the treatment of solid tumors[J].Semin Qncol,2003,30(1 Suppl 1):49-55.
  • 6Miller A B,Hoogstraten B,Staquet M,et al.Reporting results of cancer treatment[J].Cancer,1981,47(1):207-214.
  • 7Bunn P A Jr,Kelly K.New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer:a review of the literature and future directions[J].Clin Cancer Res,1998,4(5):1087-1100.
  • 8Sirotnak F M.Studies with ZD1839 in preclinical models[J].Semin Oncol,2003,30(1 Suppl 1):12-20.
  • 9Schiller J H.New directions for ZD1839 in the treatment of solidtumors[J].Semin Oncol,2003,30(1 Suppl 1):49-55.
  • 10Baselga J,Rischin D,Ranson M,et al.Phase I safety,phar macokinetic,and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types[J].J Clin Oncol,2002,20(21):4292-4302.

共引文献24

同被引文献7

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部